2023
The role of routine biopsy of the background liver in the management of hepatocellular carcinoma
Lee S, Ahmed M, Taddei T, Jain D. The role of routine biopsy of the background liver in the management of hepatocellular carcinoma. Human Pathology 2023, 138: 18-23. PMID: 37236406, DOI: 10.1016/j.humpath.2023.05.009.Peer-Reviewed Original ResearchConceptsLiver biopsyEarly HCC stagesHepatocellular carcinoma managementLarge university hospitalSeparate biopsiesCirrhosis statusClinical characteristicsClinical suspicionMedian ageEarly diseasePathology databaseRoutine biopsyHCC stageBiopsy resultsHCC patientsParenchymal findingsUniversity HospitalBackground liverHepatocellular carcinomaNontumoral liverHCC biopsiesBiopsyPatientsCirrhosisLiver
2021
Impact of NAFLD on clinical outcomes in hepatocellular carcinoma treated with sorafenib: An international cohort study.
Howell J, Samani A, Mannan B, Hajiev S, Aval L, Abdelmalak R, Tam V, Bettinger D, Thimme R, Taddei T, Kaplan D, Seidensticker M, Sharma R. Impact of NAFLD on clinical outcomes in hepatocellular carcinoma treated with sorafenib: An international cohort study. Journal Of Clinical Oncology 2021, 39: 289-289. DOI: 10.1200/jco.2021.39.3_suppl.289.Peer-Reviewed Original ResearchImpact of NAFLDOverall survivalHepatocellular carcinomaLiver diseaseNon-alcoholic fatty liver diseaseMultivariable Cox proportional hazardsAdvanced-stage hepatocellular carcinomaLower starting doseSorafenib-related toxicityFatty liver diseaseStage hepatocellular carcinomaCox proportional hazardsLogistic regression modellingStarting doseMedian BMIPrognostic factorsSpecialist centresHCC patientsNAFLDTreatment responseInternational cohortPatientsSorafenibDemographic dataSurvival
2018
Hepatocellular Carcinoma Outcome is Predicted by Expression of Neuronal Calcium Sensor 1
Schuette D, Moore LM, Robert ME, Taddei TH, Ehrlich BE. Hepatocellular Carcinoma Outcome is Predicted by Expression of Neuronal Calcium Sensor 1. Cancer Epidemiology Biomarkers & Prevention 2018, 27: cebp.0167.2018. PMID: 29789326, PMCID: PMC8465775, DOI: 10.1158/1055-9965.epi-18-0167.Peer-Reviewed Original ResearchConceptsNeuronal calcium sensor-1Hepatocellular carcinomaDisease outcomePrognostic biomarkerIncidence of HCCWorse disease outcomesCancer-related deathLiver cancer cohortExpression levelsFurther functional assessmentEarly tumor detectionProspective cohortAsian patientsPatient survivalVariety of Ca2Tumor microarrayHCC patientsMetastatic cancerBreast cancerCancer cohortAggressive phenotypeNovel biomarkersFunctional assessmentPredictive valueTumor progression
2017
Up-titration of sorafenib for hepatocellular carcinoma: Impact on duration of exposure and cost.
Kaplan D, Yu S, Taddei T, Reiss K, Mehta R, D'Addeo K, Aytaman A, Hunt K, Fox R, Baytarian M, Valdarrama A. Up-titration of sorafenib for hepatocellular carcinoma: Impact on duration of exposure and cost. Journal Of Clinical Oncology 2017, 35: 385-385. DOI: 10.1200/jco.2017.35.4_suppl.385.Peer-Reviewed Original ResearchDuration of exposureBCLC BICD9 codesBarcelona Clinic Liver Cancer stageInitiation of sorafenibMedian overall survivalLiver Cancer stageLonger exposure durationECOG PSExposure durationUp-titrationChild-TurcotteMELD scoreSorafenib therapyFirst doseOverall survivalPharmacy recordsMedian agePrescription fillsLiver diseaseTumor numberC-HCCEquivalent survivalHCC patientsCancer stageSorafenib for hepatocellular carcinoma managed by non-oncologists: Impact on drug exposure and survival.
Kaplan D, Taddei T, Mehta R, D'Addeo K, Aytaman A, Hunt K, Fox R, Baytarian M, Valdarrama A. Sorafenib for hepatocellular carcinoma managed by non-oncologists: Impact on drug exposure and survival. Journal Of Clinical Oncology 2017, 35: 404-404. DOI: 10.1200/jco.2017.35.4_suppl.404.Peer-Reviewed Original ResearchICD9 codesBarcelona Clinic Liver Cancer stageOverall median survival rateInitial dosing regimensLiver Cancer stageMedian survival rateSimilar treatment durationCTP AECOG PSExtrahepatic spreadChild-TurcotteMacrovascular invasionMELD scorePrescriber specialtyReal-world practiceMedian agePharmacy recordsSorafenib exposureBCLC 0Dosing regimensLiver diseaseTumor numberPrescribing practicesHCC patientsCancer stage